These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 2514483)

  • 21. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Costs and cost-effectiveness of colorectal cancer prevention and therapy.
    Schrag D; Weeks J
    Semin Oncol; 1999 Oct; 26(5):561-8. PubMed ID: 10528905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can factors influencing in-patient treatment in Hodgkin's disease be identified?--Retrospective analysis of HD6 patients of the GHSG.
    Pfistner B; Paulus U; Glossmann JP; Walshe R; Tesch H; Diehl V;
    Stud Health Technol Inform; 2000; 77():399-403. PubMed ID: 11187583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Evaluation of the medical and therapeutic theorical cost of bronchial asthma during the first year of its treatment (author's transl)].
    Michel FB; Terral C; Clauzel AM
    Rev Fr Mal Respir; 1979; 7(2):218-9. PubMed ID: 493703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Economic effectiveness of decreasing morbidity with temporary disability].
    Zolotarev RB
    Gig Tr Prof Zabol; 1990; (4):47-9. PubMed ID: 2376344
    [No Abstract]   [Full Text] [Related]  

  • 26. [Socioeconomic aspects of ambulatory radiotherapy].
    Vazhenin AV; Abdullina NA; Klipfel' AE; Rumiantsev AP
    Vopr Onkol; 1990; 36(4):479-82. PubMed ID: 2346000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Determination of the economic effectiveness of shortening treatment times].
    Kulagina EN
    Sov Zdravookhr; 1980; (5):25-9. PubMed ID: 6771875
    [No Abstract]   [Full Text] [Related]  

  • 28. [The economic loss caused by temporary loss of work capacity related to infectious diseases].
    Khromenkova VP
    Feldsher Akush; 1991 Aug; 56(8):7-10. PubMed ID: 1765188
    [No Abstract]   [Full Text] [Related]  

  • 29. [Socioeconomic and medico-organizational aspects of the outpatient diagnosis of surgical pathology of the lungs and mediastinum].
    Kuzin MI; Vishevskiĭ AA; Borisov VV
    Sov Zdravookhr; 1986; (8):39-42. PubMed ID: 3094166
    [No Abstract]   [Full Text] [Related]  

  • 30. [Economic effectiveness of prophylactic and therapeutic measures in cardiovascular diseases].
    Roĭtman MP; Lunskaia LL
    Sov Zdravookhr; 1982; (5):50-4. PubMed ID: 6808669
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparing costs associated with risk stratification rules for t-year survival.
    Cai T; Tian L; Lloyd-Jones DM
    Biostatistics; 2011 Oct; 12(4):597-609. PubMed ID: 21415016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenomic testing: the cost factor.
    Wedlund PJ; de Leon J
    Pharmacogenomics J; 2001; 1(3):171-4. PubMed ID: 11908752
    [No Abstract]   [Full Text] [Related]  

  • 33. Social costs of sports injuries.
    Sørensen CH; Sonne-Holm S
    Br J Sports Med; 1980 Mar; 14(1):24-5. PubMed ID: 6769529
    [No Abstract]   [Full Text] [Related]  

  • 34. The cost of malnutrition in Canada.
    Sabry ZI
    Can J Public Health; 1975; 66(4):291-3. PubMed ID: 808262
    [No Abstract]   [Full Text] [Related]  

  • 35. [Suicide and economy].
    Thörn A
    Lakartidningen; 1975 Apr; 72(16):1632-3. PubMed ID: 1128066
    [No Abstract]   [Full Text] [Related]  

  • 36. Comment on "Cost analysis and sociocultural profile of kidney patients. Impact of the treatment method".
    Arrieta-Lezama J; Selgas-Gutiérrez R
    Nefrologia; 2015; 35(1):115-6. PubMed ID: 25611840
    [No Abstract]   [Full Text] [Related]  

  • 37. Response to the comment on "Cost analysis and sociocultural profile of kidney patients. Impact of the treatment method".
    Lorenzo-Sellares V
    Nefrologia; 2015; 35(1):116. PubMed ID: 25611841
    [No Abstract]   [Full Text] [Related]  

  • 38. [The socioeconomic aspects of the therapeutic measures in lymphogranulomatosis].
    Loseva MI; Panacheva LA; Sharaputo VM
    Vopr Onkol; 1989; 35(11):1361-4. PubMed ID: 2514483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
    Beard SM; Lorigan PC; Sampson FC
    Br J Cancer; 2000 Jan; 82(1):81-4. PubMed ID: 10638970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The burden of illness associated with renal cell carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
    Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.